Physician profile
David J Freestone
NPI 1487916995
$400.87
in general payments reported to CMS, 2019-2025
9 companies · $99.40 in 2025
The $99.40 reported for 2025 was less than what a typical Pediatric Gastroenterology provider received nationally (typical 2025 total: $195).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39.51 · 2020: $5.20 · 2021: $13.03 · 2022: $122 · 2024: $122 · 2025: $99.40.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $205 · Education: $15.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $205.47 |
| Education | $15.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $122.00 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $121.73 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $41.41 | 2025 | Eohilia |
| Abbott Laboratories | $39.51 | 2019 | |
| Celltrion USA INC. | $23.17 | 2025 | Vegzelma |
| Janssen Biotech, INC. | $18.01 | 2025 | Tremfya |
| Alcresta Therapeutics, INC. | $16.81 | 2025 | Relizorb |
| Abbvie INC. | $13.03 | 2021 | |
| Travere Therapeutics, INC. | $5.20 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Freestone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.